- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Development of a Tie2-activating antibody for treating acute kidney injury (AKI) | ||||||
| Antibody | Acute Kidney Injury | Tie2 | Candidate | MabTics Co., Ltd. | RS-2023-00217918 | ||
| 2 | A Study on the lead optimization for the development of new antibody drugs for androgenic alopecia and alopecia areata | ||||||
| Antibody | Hair Loss | CXCL12 | Lead | Epibiotech | HN22C0027 | ||
| 3 | Development of T cell-recruiting bispecific antibodies targeting blood antigen-specific B cells for ABO-incompatible solid organ transplantation | ||||||
| Antibody | Organ Failure (incompatible blood type) | ABO BCR, CD3 | Hit | Korea Advanced Institute of Science and Technology | HN21C1024 | ||